Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 368 clinical trials
featured
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

breast cancer
erbb2
HER2
hormone therapy
endocrine therapy
  • 220 views
  • 24 Nov, 2020
  • 1 location
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

  • 35 views
  • 28 Mar, 2021
  • 207 locations
Breast Cancer Toxicity

The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic breast cancer. The

  • 0 views
  • 18 Mar, 2021
  • 1 location
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

  • 50 views
  • 29 Mar, 2021
  • 218 locations
Functional Precision Oncology for Metastatic Breast Cancer

This is a pilot study to assess the feasibility of comprehensive genomic characterization and drug screening in metastatic breast cancer. The trial will seek to provide personalized genomic and

  • 0 views
  • 18 Apr, 2021
  • 1 location
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer

taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer. Additionally, the study is designed to characterize the safety, the tolerability and efficacy of this

stage iv breast cancer
carboplatin
anthracyclines
taxane
  • 22 views
  • 07 Nov, 2020
  • 1 location
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer

and ifosfamide in treating women who have metastatic breast cancer.

stage iv breast cancer
tumor cells
docetaxel
  • 37 views
  • 07 Nov, 2020
  • 5 locations
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that

  • 3 views
  • 08 Apr, 2021
  • 8 locations
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

This is a one-arm, single site, open-label phase II study. Patients will be enrolled in the screening step at the start of the second line of chemotherapy, and will undergo blood draws for ctDNA detection. Patients for whom ctDNA was successfully detected and found informative by the study executive board …

  • 0 views
  • 16 Apr, 2021
  • 1 location
Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer

The primary endpoint of this phase II trial is the objective response rate of the stage I (low-dose) regimen. The secondary endpoints include treatment-related toxicity, the change in quality of life, progression free survival and overall survival.

stage iv breast cancer
metastasis
adjuvant chemotherapy
paclitaxel
immunostimulant
  • 18 views
  • 07 Nov, 2020
  • 1 location